RecruitingNCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Studying Adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massive Bio, Inc.
- Principal Investigator
- Selin Kurnaz, PhD, DMDMassive Bio, Inc.
- Intervention
- Clinical Trial Matching(other)
- Enrollment
- 50000 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2040
Study locations (30)
- Massive Bio SYNERGY-AI site, Birmingham, Alabama, United States
- Massive Bio SYNERGY-AI site, Mobile, Alabama, United States
- Massive Bio SYNERGY-AI site, Scottsdale, Arizona, United States
- Massive Bio SYNERGY-AI site, Little Rock, Arkansas, United States
- Massive Bio SYNERGY-AI site, Duarte, California, United States
- Massive Bio SYNERGY-AI site, Irvine, California, United States
- Massive Bio SYNERGY-AI site, La Jolla, California, United States
- Massive Bio SYNERGY-AI site, Orange, California, United States
- Massive Bio SYNERGY-AI site, San Francisco, California, United States
- Massive Bio SYNERGY-AI site, Stanford, California, United States
- Massive Bio SYNERGY-AI site, Aurora, Colorado, United States
- Massive Bio SYNERGY-AI site, Denver, Colorado, United States
- Massive Bio SYNERGY-AI site, Littleton, Colorado, United States
- Massive Bio SYNERGY-AI site, Hartford, Connecticut, United States
- Massive Bio SYNERGY-AI site, Norwalk, Connecticut, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03452774 on ClinicalTrials.govOther trials for Adenocarcinoma of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523529Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsBeijing Biotech
- RECRUITINGNCT07100288Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian CancerComplejo Hospitalario Universitario Insular Materno Infantil
- RECRUITINGPHASE2NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid TumorsMacroGenics
- RECRUITINGPHASE1NCT06840886A Study of PHST001 in Advanced Solid TumorsPheast Therapeutics
- RECRUITINGPHASE2NCT05500391Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringCentre Oscar Lambret
- RECRUITINGPHASE1, PHASE2NCT05922930Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE3NCT05601700Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)Ente Ospedaliero Ospedali Galliera
- ACTIVE NOT RECRUITINGPHASE2NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.